Paul Grint

Paul C.
Grint currently works at Codagenix, Inc., as Chairman & Chief Executive Officer, Cardea Bio, Inc., as Chairman from 2020, Synedgen, Inc., as Director from 2014, CONNECT, as Director, Amplyx Pharmaceuticals, Inc., as Director from 2016, January Therapeutics, Inc., as Director from 2021, Persephone Biosciences, Inc., as Director, and CRISPRQC, Inc., as Director.
Dr. Grint also formerly worked at AmpliPhi Biosciences Corp., as Chief Executive Officer & Director from 2017 to 2019, Regulus Therapeutics, Inc., as President, Chief Executive Officer & Director from 2015 to 2017, Armata Pharmaceuticals, Inc., as Chief Executive Officer, Illumina, Inc., as Independent Director from 2011 to 2013, Inhibikase Therapeutics, Inc., as Independent Director from 2020 to 2024, Pfizer Inc., as Chief Medical Officer, Schering-Plough Corp., as Chief Medical Officer, Kalypsys, Inc., as Chief Medical Officer in 2008, Cerexa, Inc., as President, IDEC Pharmaceuticals Corp., as Chief Medical Officer, Zephyr Sciences, Inc., as Chief Medical Officer & Senior Vice President, and Forest Research Institute, Inc., as Senior Vice President-Research from 2009 to 2011.
Dr. Grint received his doctorate degree from St Bartholomew's Hospital Medical College and undergraduate degree from St Mary's Hospital Medical School.